Literature DB >> 26026058

Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation.

Nathalie Niyonzima1, Eivind O Samstad2, Marie H Aune1, Liv Ryan1, Siril S Bakke1, Anne Mari Rokstad3, Samuel D Wright4, Jan K Damås1, Tom E Mollnes5, Eicke Latz6, Terje Espevik7.   

Abstract

Chronic inflammation of the arterial wall is a key element in the development of atherosclerosis, and cholesterol crystals (CC) that accumulate in plaques are associated with initiation and progression of the disease. We recently revealed a link between the complement system and CC-induced inflammasome caspase-1 activation, showing that the complement system is a key trigger in CC-induced inflammation. HDL exhibits cardioprotective and anti-inflammatory properties thought to explain its inverse correlation to cardiovascular risk. In this study, we sought to determine the effect of reconstituted HDL (rHDL) on CC-induced inflammation in a human whole blood model. rHDL bound to CC and inhibited the CC-induced complement activation as measured by soluble terminal C5b-9 formation and C3c deposition on the CC surface. rHDL attenuated the amount of CC-induced complement receptor 3 (CD11b/CD18) expression on monocytes and granulocytes, as well as reactive oxygen species generation. Moreover, addition of CC to whole blood resulted in release of proinflammatory cytokines that were inhibited by rHDL. Our results support and extend the notion that CC are potent triggers of inflammation, and that rHDL may have a beneficial role in controlling the CC-induced inflammatory responses by inhibiting complement deposition on the crystals.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26026058     DOI: 10.4049/jimmunol.1403044

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.

Authors:  Seth G Thacker; Abdalrahman Zarzour; Ye Chen; Mustafa S Alcicek; Lita A Freeman; Dennis O Sviridov; Stephen J Demosky; Alan T Remaley
Journal:  Immunology       Date:  2016-08-28       Impact factor: 7.397

Review 2.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

Review 3.  Complement-Mediated Regulation of Metabolism and Basic Cellular Processes.

Authors:  Christoph Hess; Claudia Kemper
Journal:  Immunity       Date:  2016-08-16       Impact factor: 31.745

Review 4.  Inflammasomes: a preclinical assessment of targeting in atherosclerosis.

Authors:  Jeremiah Stitham; Astrid Rodriguez-Velez; Xiangyu Zhang; Se-Jin Jeong; Babak Razani
Journal:  Expert Opin Ther Targets       Date:  2020-08-06       Impact factor: 6.902

5.  Native and oxidised lipoproteins negatively regulate the serum amyloid A-induced NLRP3 inflammasome activation in human macrophages.

Authors:  Katariina Nurmi; Katri Niemi; Ilona Kareinen; Kristiina Silventoinen; Martina B Lorey; Yan Chen; Vesa-Petteri Kouri; Jukka Parantainen; Timo Juutilainen; Katariina Öörni; Petri T Kovanen; Dan Nordström; Sampsa Matikainen; Kari K Eklund
Journal:  Clin Transl Immunology       Date:  2021-08-03

Review 6.  Cholesterol Crystal Embolism and Chronic Kidney Disease.

Authors:  Xuezhu Li; George Bayliss; Shougang Zhuang
Journal:  Int J Mol Sci       Date:  2017-05-24       Impact factor: 5.923

7.  Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis.

Authors:  Thao H P Nguyen; Ingrid Hokstad; Morten Wang Fagerland; Tom Eirik Mollnes; Ivana Hollan; Mark W Feinberg; Gunnbjørg Hjeltnes; Gro Ø Eilertsen; Knut Mikkelsen; Stefan Agewall
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

Review 8.  A novel "complement-metabolism-inflammasome axis" as a key regulator of immune cell effector function.

Authors:  Giuseppina Arbore; Claudia Kemper
Journal:  Eur J Immunol       Date:  2016-06-08       Impact factor: 5.532

9.  The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory 'M1' human macrophages.

Authors:  Nehal Narayan; Harpreet Mandhair; Erica Smyth; Stephanie Georgina Dakin; Serafim Kiriakidis; Lisa Wells; David Owen; Afsie Sabokbar; Peter Taylor
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

10.  Lower High-Density Lipoproteins Levels During Human Immunodeficiency Virus Type 1 Infection Are Associated With Increased Inflammatory Markers and Disease Progression.

Authors:  Damariz Marín-Palma; Gustavo A Castro; Jaiberth A Cardona-Arias; Silvio Urcuqui-Inchima; Juan C Hernandez
Journal:  Front Immunol       Date:  2018-06-14       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.